Despite recent market volatility and geopolitical tensions involving the US and Iran, major research houses remain bullish on several Indian equities.
Here are the top 10 “Buy” rated stocks as of April 4, 2026, categorized by their projected returns and key growth drivers.
High Conviction Picks: Over 30% Projected Upside
| Stock | Brokerage | Target Price | Potential Upside | Key Driver |
| Adani Ports | Motilal Oswal | ₹1,820 | ~39% | Integrated logistics and NQXT acquisition. |
| Petronet LNG | Nomura | ₹340 | ~37% | Attractive valuation; trading near replacement cost. |
| Kalpataru Projects | Emkay Global | ₹1,450 | 36.2% | Low West Asia exposure; strong Saudi Aramco ties. |
| BHEL | JM Financial | ₹345 | ~35% | Robust power demand and massive order book. |
| Welspun Corp | Nuvama | ₹1,082 | 33% | ₹24,700 crore order book and US expansion. |
Strong Growth Picks: 20% to 30% Projected Upside
-
Granules India (Emkay Global)
-
Target: ₹800 (29% Upside)
-
Insight: Successfully entered the high-margin US-controlled substances market (e.g., generic Vyvanse).
-
-
Varun Beverages (Ambit Capital)
-
Target: ₹501 (29% Upside)
-
Insight: Transitioning from a regional bottler to a global F&B player with a focus on Africa and new product segments.
-
-
Astral (Ambit Capital)
-
Target: ₹2,024 (26% Upside)
-
Insight: Driven by a 17% CAGR in pipe volume and backward integration into resin manufacturing.
-
-
Marico (Motilal Oswal)
-
Target: ₹900 (22% Upside)
-
Insight: Strong domestic volume growth and limited geopolitical risk (less than 5% revenue from MENA).
-
Steady Compounder: 11% Projected Upside
-
Bharat Electronics (Nomura)
-
Target: ₹454 (11% Upside)
-
Insight: Massive order inflows reaching ₹3 lakh crore in FY26, driven by large-scale defense contracts for radars and missile systems.
-
Market Context & Geopolitical Impact
The recent correction in the Nifty 50 (down 1.5%) and Sensex (down 2.5%) is largely attributed to global uncertainty. Brokerages are specifically favoring companies with low exposure to the Middle East or those operating in defensive sectors like Pharmaceuticals and FMCG.
For instance, while BHEL faces a minor revenue shortfall due to the Strait of Hormuz supply disruptions, its long-term order visibility remains a “conviction buy” for analysts.
Note: These projections are based on brokerage research as of April 2026. Market conditions can change rapidly; always consult with a financial advisor before making investment decisions.
